More CRISPR Stock Catalysts Ahead
Gene-editing stocks took a big step forward in November when CRISPR Therapeutics (NASDAQ: CRSP) reported fairly positive results from the first patients treated with a CRISPR-based drug. Early success from the present leader in the field also pushed up shares of Editas Medicine (NASDAQ: EDIT) and Intellia Therapeutics (NASDAQ: NTLA), even though neither has reported any clinical-trial results yet.
If you missed out on the latest big catalyst that drove all three CRISPR stocks higher, don't worry -- you'll get more chances soon. Here's what you need to know about the road ahead for CRISPR, Editas, and Intellia.
Image source: Getty Images.
Source Fool.com
